ORIC Q3: $345M Cash to 2H 2028, Phase 3 Started in Prostate Cancer
ORIC is trading near its 52-week low of $7.23 (4.0% above the low).
Summary
ORIC reported Q3 2026 results with $345.4M in cash, enough to fund operations into 2H 2028, and disclosed that its first Phase 3 trial (Himalayas-1) is now underway with Bayer supplying darolutamide.
Key Events · Earnings and Guidance · ORIC
-
Q3 Results and Cash Runway
Cash, cash equivalents and investments totaled $345.4 million as of September 30, 2026, expected to fund the operating plan into 2H 2028 and beyond the first Phase 3 rinzimetostat readout.
-
Loss Widens on Rinzimetostat Spend
R&D expenses rose to $43.4 million from $28.8 million a year earlier, and the net loss widened to $48.1 million ($0.44 per share) from $32.6 million ($0.33).
-
First Phase 3 Trial Initiated
Himalayas-1 will enroll approximately 600 patients across 250+ sites in 25 countries, randomizing rinzimetostat plus darolutamide against physician's choice of an AR inhibitor or docetaxel.
-
Bayer to Supply Darolutamide Free
A clinical trial collaboration and supply agreement has Bayer providing NUBEQA at no cost for Himalayas-1; ORIC keeps full global development and commercial rights to rinzimetostat.
Analysis · ORIC · Life Sciences
The quarter itself is unremarkable — R&D spend rose to $43.4M from $28.8M and the net loss widened to $48.1M — but the program updates are what matter. ORIC has now started its first Phase 3 (Himalayas-1, ~600 patients) in post-abiraterone mCRPC with Bayer supplying darolutamide at no cost, and it plans a second Phase 3 (Redwood-1) in EGFR atypical NSCLC in 1H 2027. With $345.4M in cash funding operations into 2H 2028 and past the first Phase 3 readout, the company does not need to raise money near its 52-week low to reach that data point.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORIC was trading at $7.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $779.5M. The 52-week trading range was $7.23 to $14.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.